



Supplemental Figure 1. C-peptide responses in four analyzed participants from the clinical trial. The C-peptide area under the curve during a four hour mixed meal tolerance test are shown for each subject at baseline, 13, 26, and 52 weeks. These participants were designated as “responders” because the value at 13 weeks showed a decline from the baseline of < 9.7%.

Mature naïve B cells



Supplemental Figure 2. Expression of polyreactive antibodies from mature naïve B cells isolated and cloned from a healthy donor and patients with T1D before and after Rituximab treatment. Antibodies cloned from mature naïve B cells of a healthy donor and T1D patients before and after Rituximab treatment were tested by ELISA for insulin (INS), lipopolysaccharide (LPS), and double-stranded DNA (dsDNA). Dotted lines represent the ED38-positive control and solid lines represent binding for each clone recombinant antibody. Horizontal lines define the cutoff OD₄₀₅nm for positive reactivity. Polyreactivity requires surpassing the OD₄₀₅nm threshold for all three antigens. Frequency of polyreactivity (filled area) clones is summarized in the pie charts, with the total number of clones tested indicated in the centers. T1D patients 664 and 697 have decreased frequency of polyreactive clones following Rituximab treatment while patients 375 and 518 resulted in increased frequency of polyreactive clones following anti B-cell therapy.



Supplemental Figure 3. T1D patients display similar serum BAFF concentrations before and 52 weeks after anti B-cell therapy. Serum BAFF concentrations (pg/mL) in healthy donors (open diamonds, n=50), previously studied T1D patients (black diamonds, n=6) and T1D patients enrolled by TRIALNET before and 52 weeks after Rituximab treatment (black diamonds, n=19) were measured by ELISA. Each diamond represents an individual, and the average is shown with a bar.

Supplemental Table 1. Additional clinical characteristics of research subjects

Random ID	Baseline*		12 weeks		26 weeks		39 weeks		52 weeks	
	Hb1Ac	CPEP AUC (ng/mL)	Hb1Ac	CPEP AUC (ng/mL)	Hb1Ac	CPEP AUC (ng/mL)	Hb1Ac	CPEP AUC (ng/mL)	Hb1Ac	CPEP AUC (ng/mL)
9024375	8.8	272.4	6.2	177.45	5.2	181.8	5.9	ND	6	209.475
9047518	8.6	783.075	5.4	657.525	5.8	539.25	6.2	ND	6.9	882.3
9002664	5.8	624.975	5	285.45	5.2	370.65	5.4	ND	5.6	362.025
9012697	7.6	294.975	8.1	109.725	7.2	167.4	6.4	ND	6.1	207.975
9006916	6.6	355.2	5.4	70.9125	5.6	201.975	5.8	ND	6.3	212.4
9009337	9.4	390.9	6.8	213.975	7.6	160.875	8.1	ND	7.9	260.625
9020804	5	1153.65	4.8	517.5	4.8	512.1	5.1	ND	5	765.825
9023002	7.1	916.05	6.2	627.3	7.6	498.6	ND	ND	5.8	892.725
9030498	7.8	712.575	5	362.325	5.1	424.425	5.9	ND	5.5	842.175
9039198	6.6	303.825	5.8	247.275	6.7	222.825	7	ND	8.8	235.35
9042028	6	1163.475	5.2	453.675	5.6	566.7	5.7	ND	6.1	820.125
9066896	6.5	487.725	5.9	238.125	6	235.875	5.6	ND	6	321.375
9077401	8	533.4	6.1	317.7	5.9	276.45	6.2	ND	6.6	418.275
9024930	11.9	789.15	6.4	556.05	6.3	736.125	6.5	ND	7.8	961.35
9045644	7.3	327.75	6.4	166.2	6.5	165.45	6.7	ND	6.9	300.375
9036566	6.2	555.15	6.1	316.275	6.2	319.875	7	ND	6.9	739.2
9079264	8.7	623.025	4.9	207	5.3	413.325	5.7	ND	5.3	495.3
9080594	6.9	805.425	5.2	554.475	5.3	329.25	5.8	ND	5.5	761.625
9049192	8.8	278.175	6.1	170.025	6.6	144.675	6.7	ND	6.5	209.7

*Hb1Ac collected at screen

Hb1Ac range: Baseline 5-11.9 (mean 7.56), 12 weeks 5-8.1 (mean 5.84), 26 weeks 4.8-7.2 (mean 6.03), 39 weeks 5.4-8.1 (mean 6.2), 52 weeks 5-8.8 (mean 6.39); CPEP AUC range: baseline 272.4-1163.475ng/mL (mean 598.47ng/mL), 12 weeks 70.91-657.53ng/mL (mean 328.89ng/mL), 26 weeks 144.68-736.13ng/mL (mean 340.4ng/mL), 39 weeks ND, 52 weeks 207.98-961.35ng/mL (mean 520.96ng/mL); patients highlighted were tested for reactivity

ND, Not done

Supplemental Table 2. Repertoire and reactivity of antibodies from mature naive B cells of T1D patient 664 pre treatment

Ig	HEAVY					LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3(aa)	Length	Vκ	Jκ	CDR3(aa)	Length	Poly	HEp-2	Staining
preTx mnT1D664 52	3-30-3	2-15	3	4	EGGVVATFDY	11	1-12	4	QQANSFPLT	9	-	-	-
preTx mnT1D664 54	1-69	3-3	3	6	GLSGPFAGVVKGAYYYYYMDV	22	1-5	1	QQYNSYPRT	9	+	+	-
preTx mnT1D664 59#	3-11	1-7	2	2	KWNWYFDL	8	2-29	3	MQSIQLPLFT	10			
preTx mnT1D664 64	1-3	3-9	2	4	VGYDILTYGYFDY	14	3-20	1	QQYGSSPWT	9	-	+	-
preTx mnT1D664 68	1-69	3-22	2	1	ETREYYDSSGYFYGFQH	19	4-1	3	QQYYSTPFG	9	-	-	-
preTx mnT1D664 69#	1-69	3-22	2	4	KGGGNYDSSGYDY	16	1-13	3	QQFNSYLLFT	10			
preTx mnT1D664 70	3-7	2-15	2	4	DLFAGYCSGGSCYFFFGRGFDY	22	3-20	2	QQYGSSPRMYT	11	+	-	-
preTx mnT1D664 72	3-33	2-2	2	4	SGYCSSTSCYHFDY	14	3-20	3	QQYGSSFT	8	-	+	-
preTx mnT1D664 73#	4-31	/	/	6	DRGRSGHTSYYYMDV	17	1-39	2	QQSYSTPYT	9			
preTx mnT1D664 75#	1-69	4-17	3	6	TPPMATVTTNAYYGMVDV	16	1-12	4	QQANSFPVT	9			
preTx mnT1D664 76	4-39	3-10	1	4	RGLLWFPTEPYFDY	15	3-20	4	QQYGSSPLT	9	+	-	c
preTx mnT1D664 79#	3-21	/	/	4	DLGPVRI	7	3-20	2	QQYGSSPRYT	10			
preTx mnT1D664 80	1-46	2-21	2	3	ACGGDCFAFDI	11	3-20	1	QQYGSSLWT	9	-	-	-
preTx mnT1D664 82	4-59	5-5	2	6	DRGYSYGLYYYYMDV	16	1-33	3	QQYDNLHIFT	10	-	-	-
preTx mnT1D664 83	3-33	3-3	1	4	EAQRFLWLFPPPTAPIDY	19	1-12	4	QQANSFPPT	8	+	+	c
preTx mnT1D664 84	1-69	3-22	2	4	GYKYDSSGYQYFDY	16	1-5	2	QQYNSYT	7	-	-	-
preTx mnT1D664 88	1-69	3-22	2	3	DGGSDGSGYDAFDI	15	4-1	4	QQYYSTPLT	9	-	-	-
preTx mnT1D664 90	1-46	4-17	3	4	DSADTVTEYFDY	14	3-11	4	QQRSNWPLT	10	-	-	-
preTx mnT1D664 91	4-34	6-6	2	4	EPSSYLDY	9	1-8	4	QQYYSYPLT	9	-	+	-
preTx mnT1D664 92	3-23	/	/	6	TGYYYYGMDV	10	1-16	2	QQYNSYPLYT	10	+	+	-
preTx mnT1D664 94	4-31	2-3	3	5	AAATVWDNWFDP	12	3-15	2	QQYNWPPFYT	11	+	+	-
preTx mnT1D664 95#	5-a	6-13	2	4	LGPLYSSWGYFDY	14	1-5	1	QQYNSYSQT	9			
preTx mnT1D664 96#	1-69	2-2	3	6	AGFLPAIYYGMDV	15	4-1	1	QQYYSTTWT	9			
preTx mnT1D664 57	1-2	3-10	1	5	ETGPGEDGNNWFDP	14							
	VH	D	RF	JH	CDR3(aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	HEp-2	Staining
preTx mnT1D664 53	4-59	3-22	2	4	GDYDSSGYNDY	12	3-21	3	QVWDSSSPL	9	-	-	-
preTx mnT1D664 55	4-34	2-15	2	5	APRRPYCSGGSCYSDPRMGNWFDP	24	2-14	1	SSYTSSTKV	10	+	+	c
preTx mnT1D664 56	3-33	3-3	2	6	EGSRDFWSGYWGSYYGMDV	20	2-14	3	SSYTSSTPVV	11	+	+	-
preTx mnT1D664 58	1-69	/	/	6	GSRWPGMDV	9	2-8	1	SSYAGSNTL	9	+	-	-
preTx mnT1D664 60#	1-46	3-22	2	4	GYYYDSSGYFGNY	13	3-10	3	YSTDSSGNHRGV	12			
preTx mnT1D664 61	3-48	/	/	6	LDPNYYYYGMDV	12	5-37	2	MIWPSNAKV	9	-	-	-
preTx mnT1D664 67	3-23	5-5	2	4	DTVGYSYGATFDY	13	1-51	2	GTWDSLSAVV	11	-	-	-
preTx mnT1D664 71	4-30-4	/	/	4	AWGYFDY	8	1-47	3	AAWDDSLSGRGV	12	-	-	-
preTx mnT1D664 77	1-69	1-26	2	4	EAAGVAGSYESYY	13	1-47	2	AAWDDSLSGVV	11	-	-	-
preTx mnT1D664 83#					see kappa		1-40	1	QSYDSSLSVSYV	12			
preTx mnT1D664 86	4-4	5-12	3	6	DIVRFHGYYYGMDV	14	1-47	2	AAWDDSLSGYVV	12	+	+	A
preTx mnT1D664 93	4-39	3-22	2	4	SNSSGYYY	8	3-25	1	QSADSSGTYY	10	-	-	-

RF, reading frame; #, antibody failed to be expressed

-, non-reactive; +, reactive

c, diffuse cytoplasmic staining; A, actin staining; G, golgi staining; M, mitochondria staining; N, nuclear staining

SUPPLEMENTAL TABLE 3

Supplemental Table 3. Repertoire and reactivity of antibodies from mature naive B cells of T1D patient 697 pre treatment

Ig	HEAVY					LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3(aa)	Length	Vk	Jk	CDR3(aa)	Length	Poly	HEp-2	Staining
preTx mnT1D697 1	4-34	3-3	2	1	SPYYDFWSGYKFFQH	16	3-15	2	QQYNNWRT	8	+	+	-
preTx mnT1D697 2	3-23	3-10	2	4	GLWYYYGSGVVFDY	14	3-20	1	QQYGSSPWT	9	+	+	-
preTx mnT1D697 3#	4-34	3-22	2	4	GSLAFYDSSGYNY	13	1-33	5	QQYDNLPIIT	9			
preTx mnT1D697 4	3-23	3-22	2	4	EAWDSSGYFFDY	12	4-1	2	QQYYSTQYT	9	-	-	-
preTx mnT1D697 5	3-30	3-3	1	5	DVLRFLWFQQRNWFDP	17	1-39	2	QQSYSTPRYT	10	+	+	-
preTx mnT1D697 10	4-49	5-5	3	6	DGVVTDPIYYYGMDV	16	3-15	2	QQYNNWYT	8	-	-	-
preTx mnT1D697 11	4-59	6-6	2	2	VNEYSSLGSYWFDL	15	1-39	1	QQSYSTLWT	9	-	-	-
preTx mnT1D697 17	3-9	1-26	2	4	DINPKTGSYSHQLDY	16	1-6	1	LQDYNYRT	8	-	+	-
preTx mnT1D697 20	1-69	2-2	3	6	EGQQSVPAALGGLAYYYYMDV	22	1-39	2	QQSYSTPPIT	10	+	-	-
preTx mnT1D697 33	3-15	/	/	3	FPHYAFDI	8	2-20	2	MQGTHWPPYT	10	+	+	-
preTx mnT1D697 34	4-59	5-24	2	4	DDPVLDSFDY	10	3-11	5	QQRSNWPPIT	10	-	-	-
preTx mnT1D697 44#	1-2	5-5	2	4	DIAGYSLD	8	3-20	3	QQYGSSPVT	9			
preTx mnT1D697 46	3-53	/	/	4	PLYGTGD	7	3-20	1	QQYGSSPWT	9	-	-	-
preTx mnT1D697 47	3-30	5-12	3	6	DFDIVATGYYYYGMDV	17	2-28	3	MQALQTAFT	9	-	-	-
preTx mnT1D697 48	1-2	/	/	6	ASVPFEGMDV	10	2-28	2	MQALQTRYT	9	-	-	-
preTx mnT1D697 14	3-30	1-26	1	4	GGWELSSIDY	10							
preTx mnT1D697 29	4-34	/	/	3	DADPA	5							
preTx mnT1D697 8							1-39	4	QQSYSTPLT	9			
preTx mnT1D697 16							4-1	2	QQYYSTPYT	9			
preTx mnT1D697 21							3-11	5	QQRSNWPRIT	11			
	VH	D	RF	JH	CDR3(aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	HEp-2	Staining
preTx mnT1D697 6	4-59	6-13	2	2	DTSSSWHGSYFDL	13	3-21	3	QVWDSSSDHRV	11	-	+	-
preTx mnT1D697 9	5-51	5-5	3	4	QDTAMVTIDY	10	2-14	1	SSYTSSSTLV	10	-	-	-
preTx mnT1D697 13	1-18	4-17	2	4	SDYGDHTWRRYAASGY	16	3-25	3	QSADSSGTSWV	11	+	+	-
preTx mnT1D697 14	3-30	1-26	1	4	GGWELSSIDY	10	3-27	3	YSAADNNWV	9	-	+	N
preTx mnT1D697 22	3-30	6-6	2	4	SEYSSSAVDY	11	3-1	2	QAWDSSTAV	9	-	+	-
preTx mnT1D697 24	3-23	2-21	2	4	DVCGGDCYSPFFDY	14	1-47	3	AAWDDSLSGPV	11	-	+	c
preTx mnT1D697 25	1-69	2-15	2	4	AEHCSGGSCYSTPYFFDY	18	2-11	3	CSYAGSYTWV	10	+	-	-
preTx mnT1D697 27	5-51	3-22	2	4	LVSSSGYYYGY	11	1-40	2	QSYDSSFVV	9	-	+	-
preTx mnT1D697 28#	5-51	/	/	5	MVDRDWFDP	9	3-25	3	QSADSSGTFWV	11			
preTx mnT1D697 35	4-59	3-3	2	3	TLTYDFWSGSSNAFDI	17	2-23	2	CSYAGSSTPVV	11	+	-	-
preTx mnT1D697 39	3-33	3-16	2	2	DQDYGSNPTDWFYFDL	15	1-36	3	AWDDSLNGPV	10	-	-	-
preTx mnT1D697 45	3-30	5-5	2	4	DHYSYGSDY	9	3-25	3	QSADSSGTWV	10	-	+	-

RF, reading frame; #, antibody failed to be expressed

-, non-reactive; +, reactive

c, diffuse cytoplasmic staining; A, actin staining; G, golgi staining; M, mitochondrial staining; N, nuclear staining

Supplemental Table 4. Repertoire and reactivity of antibodies from mature naive B cells of T1D patient 375 pre treatment

Ig	HEAVY					LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3 (aa)	Length	Poly	HEp-2	Staining
preTx mnT1D375 60	3-33	6-19	3	4	EGPFGGVAGKTTLYYFDY	18	3-20	3	QQYGSLSFT	9	-	-	-
preTx mnT1D375 63	3-49	3-10	2	4	SLTGPYYYGSGSYR	14	4-1	4	QQYYSTPLT	9	-	-	-
preTx mnT1D375 66	3-48	6-19	2	3	TYSSGWFDALDI	12	1-39	4	QSYSTPRRT	9	-	-	-
preTx mnT1D375 68	3-53	2-15	2	3	DSYCSGGSCPNALDI	15	1-39	1	QSYSTPRRT	10	-	-	-
preTx mnT1D375 69	3-23	3-10	3	4	RGITMVRGVIKEY	13	2-28	1	MQALQTRT	8	+	+	c
preTx mnT1D375 74	3-30	5-12	2	5	SGYSGYDFRNWFDP	14	3-20	3	QQYGSSYT	8	-	+	-
preTx mnT1D375 75	3-30	3-10	2	4	DSNGSGSSWMMYYFDY	16	3-20	1	QQTGSWT	7	-	-	-
preTx mnT1D375 76	3-23	4-17	3	4	APYRGVTTGG	10	3-15	2	QQYNNWPCS	9	+	+	-
preTx mnT1D375 79	4-30-2	4-17	2	3	VGYGDYSALDI	12	1-39	3	QSYSTPF	8	-	+	-
preTx mnT1D375 82	4-59	3-10	2	3	AAYGSGSYNVGLGALDI	19	1-5	2	QQYNSYPCS	9	-	-	-
preTx mnT1D375 83	3-7	3-3	2	4	TYDFWVSGYLDY	11	3-15	1	QQYNNWRT	8	-	-	-
preTx mnT1D375 85	4-59	4-4	2	5	GRSNDYSNFWFDP	13	2-28	2	MQALQTPYT	9	-	-	-
preTx mnT1D375 87	7-4-1	2-15	2	5	SSAYCSGGSCYSILSAYNWFDP	22	1-27	3	QKYNAPFT	9	+	+	-
preTx mnT1D375 89	3-33	/	/	4	GMGY	4	1-16	4	QQYNSYPLT	9	-	+	N
preTx mnT1D375 96	3-30	/	/	4	WGDAQEATLDY	11	3-11	2	QQRSNWPVCS	10	-	-	-
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	Poly	HEp-2	Staining
preTx mnT1D375 49	5-a	3-22	2	5	QGENYYDSSGFDP	13	2-23	1	CSYAGSSTLYV	11	-	-	-
preTx mnT1D375 61	3-23	5-12	2	3	DRYSGYDSHALDI	13	3-21	3	QVWSSSDHPV	11	-	-	-
preTx mnT1D375 64	3-73	2-21	2	4	GDCSIAKTDY	10	1-47	3	AAWDDSLSGRV	11	-	+	N
preTx mnT1D375 73	4-39	3-10	3	4	TFPMVRGVNPL	12	1-47	3	AAWDDTLGQV	11	-	+	c
preTx mnT1D375 81	3-23	/	/	4	DVLSGRVPLNYFDY	14	3-25	2	QSADSSGTYVV	11	-	+	-
preTx mnT1D375 84	4-39	4-17	2	5	HDYGDYTEGSNWFDP	15	1-44	1	AAWDDSLKYV	10	-	-	-
preTx mnT1D375 85#					see kappa		3-1	2	QAWDSSTVV	9			

RF, reading frame; #, antibody failed to be expressed

-, non-reactive; +, reactive

c, diffuse cytoplasmic staining; A, actin staining; G, golgi staining; M, mitochondria staining; N, nuclear staining

Supplemental Table 5. Repertoire and reactivity of antibodies from mature naive B cells of T1D patient 518 pre treatment

Ig	HEAVY						LIGHT					REACTIVITY			
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3(aa)	Length	Poly	HEp-2	Staining		
preTx mnT1D518 49	4-30-4	4-4	2	4	EDYDYSLIY	9	1-39	3	QQSYSTPFT	9	-	-	-		
preTx mnT1D518 54	3-7	2-2	2	6	EDWYCSSTSCYTVYYMDV	19	3-20	2	QQYGSSPPYT	10	-	+	-		
preTx mnT1D518 58	3-21	3-10	3	4	DFRRVRGIGY	11	3-15	1	QQYNNWPQT	9	+	+	N		
preTx mnT1D518 61	3-30	3-10	2	4	DIGYYGSGSYYPDY	14	3-11	4	QQRSNWQVT	9	-	-	-		
preTx mnT1D518 64	3-30	2-15	3	4	FSVVGRDY	8	3-11	4	QQRSNWPGLT	10	-	+	N		
preTx mnT1D518 65	4-34	2-2	3	4	GPRFYKVPAAFRRYFDY	18	3-15	1	QQYNNWPWT	9	+	+	c		
preTx mnT1D518 71	4-34	/	/	3	GRAFDI	6	3-11	1	QQRSNWPT	8	-	+	-		
preTx mnT1D518 72	4-59	4-17	1	3	DLLSNVGGDYVSGFDI	16	1-39	1	QQSYSTLRT	9	-	-	-		
preTx mnT1D518 73	4-34	6-13	3	5	GKVSPPIAAAGTSSWFDP	19	3-20	4	QQYGSSLLT	9	-	-	-		
preTx mnT1D518 75	3-43	6-13	2	4	DIGDSSSYFFDY	13	1-39	2	QQSYSTPRYT	10	-	-	-		
preTx mnT1D518 84	3-33	6-19	3	2	DHAIAVAGLWYFDL	14	3-15	4	QQYNNWPFLT	10	-	+	-		
preTx mnT1D518 86	3-23	1-26	3	4	EGIVGATPAPNFFDY	15	1-16	4	QQYNSYPLT	9	-	-	-		
preTx mnT1D518 95	1-69	4-17	3	2	VGRAGGMTTVTTKYFDL	17	3-20	3	QQYGSSLLT	8	+	+	c		
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	HEp-2	Staining		
preTx mnT1D518 57	4-39	5-12	2	4	EPDSGYDPIHYFDY	14	3-21	3	QVWDSSSDHRV	11	-	-	-		
preTx mnT1D518 63	4-34	3-10	2	5	GLYSGSLLYRWFDP	15	3-21	2	QVWDSSSDHVV	11	-	-	-		
preTx mnT1D518 76	1-18	6-19	3	5	VVAGTEGWFDP	11	3-1	3	QAWDSSTYVV	10	-	-	-		
preTx mnT1D518 78	4-59	5-24	2	5	ERNGYNLWFDP	12	1-51	2	GTWDSSLSAVV	11	-	-	-		
preTx mnT1D518 83	5-51	5-24	2	3	RGDRDGYNYAFDI	13	2-23	3	CSYAGSSTV	9	-	-	-		
preTx mnT1D518 87	3-30-3	6-13	1	4	DLEQLVRYFFDY	13	3-1	3	QAWDSSTHVV	10	-	-	-		
preTx mnT1D518 89	4-39	6-6	3	3	QGIAARSVDAFDI	13	2-11	2	CSYAGSYTWW	10	-	-	-		

RF, reading frame; #, antibody failed to be expressed

-, non-reactive; +, reactive

c, diffuse cytoplasmic staining; A, actin staining; G, golgi staining; M, mitochondrial staining; N, nuclear staining

Supplemental Table 6. Repertoire and reactivity of antibodies from mature naive B cells of T1D patient 664 post treatment

Ig	HEAVY					LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3(aa)	Length	Vκ	Jκ	CDR3(aa)	Length	Poly	HEp-2	Staining
postTx mnT1D664 3	4-59	4-17	2	5	AAGDYVPWRPVDWFDP	16	4-1	1	QQYYSTPWT	9	-	-	-
postTx mnT1D664 6	1-46	6-19	2	6	MRSGWYEEYYYGMDV	15	1-16	2	QQYNSYPYT	9	+	+	c
postTx mnT1D664 9#	1-18	3-3	2	6	VDGTNLNYDFWSWVGNYYGMDV	22	1-39	2	QQSYSTLCT	9			
postTx mnT1D664 10#	3-30	2-8	2	6	DLGYCTNGVCYRYMDV	16	3-20	5	QQYGSSPPEVT	11			
postTx mnT1D664 11	3-21	/	/	5	DPFSLDSPESLFGVGDARPS	20	3-20	1	QQYGSSPTWT	10	-	-	-
postTx mnT1D664 13	4-39	3-3	3	4	LYVTIFGLRGDYFDY	15	4-1	2	QQYYSTPYMYT	11	+	-	-
postTx mnT1D664 17#	1-69	5-12	3	6	EPPVDIVATINYGMDV	16	1-39	2	QQSYSTPRT	9			
postTx mnT1D664 18	3-33	3-3	1	6	DLVRFLEWLNVPYDGMVDV	18	1-6	2	LQDYNYPHT	9	+	-	-
postTx mnT1D664 23	4-34	6-13	2	3	GLRYSSSWLWGVAFDI	16	1-39	2	QQSYSTPQT	9	-	+	-
postTx mnT1D664 25	3-30	3-22	2	1	DYYDSSGYYYGHFQH	15	3-11	1	QQRSNWRWA	9	-	-	-
postTx mnT1D664 26	3-33	1-20	3	5	DPGTLVGDWFDP	12	3-11	3	QQRSNWPPIFT	11	-	-	-
postTx mnT1D664 29	3-7	3-10	1	2	VLIWFGHRWYFDL	13	1-8	3	QQYYSYPIT	9	+	-	-
postTx mnT1D664 31	4-59	3-22	2	4	EIAYYYYDY	8	2-24	2	MQATQFPYT	9	-	-	-
postTx mnT1D664 33	1-18	4-4	2	4	DAPGNYGLRPVLDY	14	3-20	3	QQYGSSPRFT	10	-	-	-
postTx mnT1D664 34	3-23	3-22	2	4	DSYYYDSSGKY	11	2-24	1	MQATQFPWT	9	-	-	-
postTx mnT1D664 40#	7-4-1	3-22	2	5	DWDYYDSSVGP	11	1-5	2	QQYNSYSGYT	10			
postTx mnT1D664 41	3-73	3-22	2	5	QLGYDSSGYGNWFDP	15	4-1	4	QQYYSTPLT	9	-	-	-
postTx mnT1D664 42	3-33	4-23	3	4	GGTSMITVGVYFDY	15	1-12	1	QQANSFPQT	9	-	+	-
postTx mnT1D664 43	4-31	3-10	2	3	VRSRGWSNLTAFDI	14	1-39	1	QQSYSTPWT	9	+	+	N
postTx mnT1D664 44	3-11	4-17	2	2	SSHYGEPYWFYFDL	13	1-39	3	QQSYSTPFT	9	-	-	-
postTx mnT1D664 45	1-69	3-10	3	4	ANITMVRGVIMPFYD	15	3-20	1	QQYGSSPWT	9	+	+	-
postTx mnT1D664 48#	1-24	2-2	1	5	IQYQLLSGNWFDP	13	3-11	4	QQRSNWPPLT	10			
postTx mnT1D664 19	3-30	3-16	1	3	VVRLGELSLYRAFDI	15							
postTx mnT1D664 22	1-18	6-19	3	3	GQEGVAVAGNDAFDI	15							
postTx mnT1D664 24							2-28	4	MQALQTLT	8			
postTx mnT1D664 38							3-20	5	QQYGSSPPIT	10			
	VH	D	RF	JH	CDR3(aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	HEp-2	Staining
postTx mnT1D664 1	4-30	2-8	2	5	GGYCTNGVCYSWWFDP	16	1-47	3	AAWDDSLSGREV	12	-	-	c
postTx mnT1D664 2	3-21	6-25	2	6	TDIISDYGMDV	11	2-11	2	CSYAGSYT	8	-	-	-
postTx mnT1D664 7	3-30	6-19	2	4	DGFSGWYGVY	10	3-10	1	YSTDSSGNHSGV	12	-	+	N
postTx mnT1D664 14	3-33	6-6	3	4	DGVAAARLDY	10	3-25	2	QSADSSGTYYV	11	-	-	-
postTx mnT1D664 28	3-7	/	/	4	TLQTKNPGKY	10	3-10	3	YSTDSSGNHGV	11	-	+	-
postTx mnT1D664 37#	3-23	3-3	3	3	DFVGVVIPHDAFDI	14	3-9	1	QVWDSSTAFYV	11			
postTx mnT1D664 41#					see kappa		1-40	2	QSYDSSLGPPV	12			
postTx mnT1D664 42#					see kappa		2-23	1	CSYAGSSTYV	10			
postTx mnT1D664 44#					see kappa		2-8	3	SSYAGSNKKV	10			
postTx mnT1D664 46	4-59	6-6	2	4	VGYGSSWDFDY	11	1-40	2	QSYDSSLVTV	11	-	-	-

RF, reading frame; #, antibody failed to be expressed

-, non-reactive; +, reactive

c, diffuse cytoplasmic staining; A, actin staining; G, golgi staining; M, mitochondrial staining; N, nuclear staining

Supplemental Table 7. Repertoire and reactivity of antibodies from mature naive B cells of T1D patient 697 post treatment

Ig	HEAVY						LIGHT				REACTIVITY		
	VH	D	RF	JH	CDR3(aa)	Length	Vk	Jk	CDR3(aa)	Length	Poly	HEp-2	Staining
postTx mnT1D697 49#	1-18	3-10	2	5	DWYGSYSYTDNWFDP	16	1-8	1	QQYYSYPR	10			
postTx mnT1D697 51#	3-15	1-26	2	6	NLPDSSGYSWPHYYYGMDV	20	1-5	1	QQYNSYSPS	9			
postTx mnT1D697 53#	3-23	2-2	3	3	EIVVPAVHWGPDAFDI	17	1-8	2	QQYYSYPYT	9			
postTx mnT1D697 54	3-23	6-19	2	4	DRGYSWGWAYDY	12	1-39	2	QQSYSTLMYT	10	-	-	N
postTx mnT1D697 55	1-8	3-10	2	4	APFLYGSPDLDY	12	2-28	4	MQALQTLT	8	-	-	-
postTx mnT1D697 56	3-23	6-19	2	4	DSEDSGSGWYGY	11	3-20	2	QQYGSSPYT	9	-	-	-
postTx mnT1D697 59	1-46	3-3	3	5	DPFKVLAIFGVVPTNWFDP	20	3-20	2	QQYGSSPGGYT	11	+	+	-
postTx mnT1D697 60	3-33	6-19	2	3	DPPPYSSGPGTGNDAFDI	18	2-28	4	MQALQTPLT	9	-	-	-
postTx mnT1D697 67	3-15	3-10	2	4	DPLTYYYGSGYSYGFY	17	3-15	1	QQYNNWGSWT	10	-	+	-
postTx mnT1D697 68	3-11	3-10	1	5	DRKILWFGELFDGDP	15	3-20	1	QQYGSSPGT	9	+	-	-
postTx mnT1D697 71	3-23	3-3	3	5	GSGGVVNNWFDP	12	4-1	4	QQYYSTPPT	9	-	+	c
postTx mnT1D697 72#	3-49	1-26	2	3	GGSYFRDYAFDI	12	4-1	2	QQYYSTPLT	9			
postTx mnT1D697 76	4-31	2-15	2	6	LYCSGGSCYSYYYGMDV	19	3-11	3	QQRSNWFT	8	-	+	-
postTx mnT1D697 78#	1-18	6-19	2	6	EGYSSGWYGIKHPYYYGMDV	21	1-33	2	QQYDNLPET	9			
postTx mnT1D697 81#	3-66	3-10	2	5	DYYGSGKTRGDNWFDP	16	1-39	1	QQSYSTPPT	9			
postTx mnT1D697 82	4-39	6-19	3	5	NFFWGIAGTFWGQRKNWFDP	22	1-39	2	QQSYSTPRT	9	+	+	c
postTx mnT1D697 83	4-4	2-2	2	2	SGYCSSTSCYRGYWFDL	18	3-20	4	QQYGSSPPLT	10	+	-	-
postTx mnT1D697 84	3-33	3-22	2	5	NTYYDSSGYNWFDP	16	1-39	2	QQSYSTLMYT	10	-	-	-
postTx mnT1D697 85	4-59	/	/	6	QARAMDV	7	3-20	5	QQYGSSPIT	9	-	-	-
postTx mnT1D697 86	3-7	3-10	2	4	DKDYGGSEFDY	11	3-15	4	QQYNNWPLT	9	-	-	-
postTx mnT1D697 88	3-23	6-19	3	4	DRRIAVAFMSPYFDY	15	3-11	1	QQRSNWPWT	9	+	-	-
postTx mnT1D697 91	1-46	3-9	2	5	DAPGYDILTGMGWDFP	17	3-20	1	QQYGSSPPTWT	11	-	-	-
postTx mnT1D697 92	4-34	2-15	2	4	RYCSGGSCPIDY	12	1-39	3	QQSYSTPFT	9	-	+	-
postTx mnT1D697 95	3-33	/	/	4	DSRYFDY	7	1-17	3	LQHNSYPFT	9	-	+	-
postTx mnT1D697 57	3-23	/	/	4	GKRHFYD	7							
postTx mnT1D697 62							3-20	1	QQYGKSPWT	10			
postTx mnT1D697 93							3-15	1	QQYNNWPQT	9			
postTx mnT1D697 96							1-5	1	QQYNSYSLT	9			
	VH	D	RF	JH	CDR3(aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	HEp-2	Staining
postTx mnT1D697 52#	3-15	3-22	2	3	DLALYDSSGYYSASFID	18	3-21	2	QVWDSSSDHPV	11			
postTx mnT1D697 58	4-59	6-13	2	4	LSKDSSWYGY	10	2-14	2	SSYTSSTLV	10	-	-	-
postTx mnT1D697 64	3-21	3-22	2	4	DFGHYDSSGDVNY	13	1-44	3	AAWDDSLNGFVW	12	-	-	-
postTx mnT1D697 65	1-8	6-19	2	4	LLGNSGWYDY	10	1-44	1	AAWDDSRMVS	10	-	-	-
postTx mnT1D697 73	1-18	5-5	3	4	DQAMVSGEIDY	11	2-14	2	SSYTSSTLYV	12	-	-	-
postTx mnT1D697 75	1-18	3-22	2	5	LDYYDSRWDFP	11	1-44	2	AAWDDSLNGPV	11	-	+	-
postTx mnT1D697 79	3-72	3-16	3	6	WIVSYYMDV	10	3-21	3	QVWDSSSDHPV	11	-	-	-
postTx mnT1D697 80	3-33	6-13	3	4	DDGIAAAGPLHFDY	14	3-21	3	QVWDSSSDHPV	11	-	-	-
postTx mnT1D697 89	4-39	6-19	2	4	RDSSGLDY	8	2-14	3	SSYTSSTWV	10	-	-	-
postTx mnT1D697 90	3-23	3-22	2	6	DNGPAQNYDSSGYYYGMDV	20	3-1	3	QAWDSSTPWV	10	-	-	-
postTx mnT1D697 61							2-11	3	CSYAGSYTWV	10			

RF, reading frame; #, antibody failed to be expressed

-, non-reactive; +, reactive

c, diffuse cytoplasmic staining; A, actin staining; G, golgi staining; M, mitochondrial staining; N, nuclear staining

Supplemental Table 8. Repertoire and reactivity of antibodies from mature naive B cells of T1D patient 375 post treatment

Ig	HEAVY						LIGHT				REACTIVITY		
	VH	D	RF	JH	CDR3(aa)	Length	V _k	J _k	CDR3(aa)	Length	Poly	HEp-2	Staining
postTx mnT1D375 02	3-23	3-22	2	4	PPRGYYEPAQN	11	1-5	1	QQYNSYSST	9	-	+	c
postTx mnT1D375 07	4-59	5-24	2	4	SYGYNLYFDY	11	3-11	5	QQRSNWPPIT	11	-	+	-
postTx mnT1D375 08	1-2	6-13	3	2	GGGIAAAIPLHWYFDL	17	1-5	3	QQYNSYSPFT	10	+	+	-
postTx mnT1D375 09	3-23	3-3	2	4	FTGFYDFWSGYEGELFDY	18	1-27	1	QKYNSAPWT	9	-	-	-
postTx mnT1D375 11	4-4	1-20	2	4	DDWNESIDY	9	1-8	1	QQYYSYPRT	9	-	+	c
postTx mnT1D375 16	4-59	3-22	2	2	ENYYDSSGYRYFDL	14	3-11	5	QQRSNWIT	8	-	-	-
postTx mnT1D375 17	3-30-3	3-10	2	4	DTWPTYGSGSYSIFDY	16	1-39	3	QQSYSTRFT	9	-	-	-
postTx mnT1D375 18	3-33	4-4	2	6	DGGRGDYSYYYYGMDV	16	1-27	3	QKYNSAPFT	9	-	-	-
postTx mnT1D375 19	3-7	3-10		6	GVIVAVYYYYGMDV	14	3-15	1	QQYNNWWT	8	+	-	N
postTx mnT1D375 29	7-4-1	5-12	2	3	DCCYEPHAFDI	11	1-39	1	QQSYSTRT	8	-	-	-
postTx mnT1D375 37	3-66	7-27	3	4	GGLGNWGADY	10	1-5	3	QQYNSYSPLFT	11	-	-	-
		3-16	2										
postTx mnT1D375 38	4-30-2	2-15	2	2	GGGKGSYWYFDL	12	3-15	1	QQYNNWPRT	9	+	+	N
postTx mnT1D375 39	3-23	4-17	2	3	GSYGDYAA	8	1-5	1	QQYNSYPWT	9	-	+	c
postTx mnT1D375 40	1-3	6-13	3	4	GTGIAAAAPPHFDY	14	2-28	4	MQALQTPFT	9	-	+	-
postTx mnT1D375 41	3-30	6-13	2	5	VSFSSSWYWFDP	12	1-9	4	QQLNSYPLT	9	+	+	c
postTx mnT1D375 42	3-53	3-3	2	4	EVVYVSGSYSY	11	1-39	2	QQSYSTPYT	9	-	-	-
	VH	D	RF	JH	CDR3 (aa)	Length	V _λ	J _λ	CDR3 (aa)	Length	Poly	HEp-2	Staining
postTx mnT1D375 03	4-31	3-22	2	3	AQPYYYSIAFDI	13	3-21	1	QVWDSSSDLNYV	12	+	-	-
postTx mnT1D375 05	4-39	6-13	2	5	QSSSRNWFDP	10	1-51	2	GTWSSLSAVV	11	-	+	-
postTx mnT1D375 10	4-31	4-17	2	6	VGYGDPRIHYYYMDV	16	1-40	3	QSYDSSLGFWV	12	-	+	-
postTx mnT1D375 22	3-30-3	2-8	2	4	DRGGGPMVSFDY	12	2-11	2	CSYAGSYTFGVV	12	-	-	-
postTx mnT1D375 24	4-39	2-15	2	3	HCSGGSCGLDDAFDI	15	1-44	1	AAWDDSLNGYV	11	-	-	-
postTx mnT1D375 25	3-15	5-12	2	4	LWGYEVGDY	9	3-25	1	QSADSSGTLYV	12	-	+	-
postTx mnT1D375 26	4-59	4-17	3	6	DRGTVTYYYYYGMVDV	16	1-40	2	QSYDSSLVYVV	12	-	-	-
postTx mnT1D375 32	1-2	3-3	2	3	TQKWFPLPDAFDI	14	1-40	2	QSYDSSLGYVV	12	+	+	-
postTx mnT1D375 44	4-49	3-16	2	4	AGRVDYYDFDY	11	2-14	2	SSYTSSSTPVV	11	-	-	-
postTx mnT1D375 45	5-a	3-22	2	4	RYYYDSSGYDY	12	2-23	2	CSYAGSSTSVV	11	-	+	-

RF, reading frame; #, antibody failed to be expressed

-, non-reactive; +, reactive

c, diffuse cytoplasmic staining; A, actin staining; G, golgi staining; M, mitochondria staining; N, nuclear staining

Supplemental Table 9. Repertoire and reactivity of antibodies from mature naive B cells of T1D patient 518 post treatment

Ig	HEAVY						LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3(aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	HEp-2	Staining	
postTx mnT1D518 03	3-30	6-19	3	4	GGIAVDIRGYFDY	13	1-5	1	QQYNSYWT	8	-	-	c	
postTx mnT1D518 06	4-59	2-8	2	6	LMVYASSPYPADMHLNYYYYGMDV	24	3-20	4	QQYGSSPIT	9	-	+	-	
postTx mnT1D518 07	4-4	5-5	2	4	VSAMDEGRYYFDY	13	3-11	4	QQRSNWPPLT	10	-	-	-	
postTx mnT1D518 08	1-18	6-13	2	6	DRGVAAAGDYYYYYGMDV	18	3-15	3	QQYNNWPLT	9	-	-	-	
postTx mnT1D518 09	3-23	3-9	3	4	DPTIFCPVDY	10	1-39	4	QQSYSTPSLT	10	+	+	-	
postTx mnT1D518 11	1-2	6-13	3	2	GGIAAAIPLHWYFDL	17	4-1	4	QQYSTPLT	9	-	-	-	
postTx mnT1D518 19	1-69	/	/	5	ASQGGGIDWFDP	12	1-39	1	QQSYSTPWT	9	+	-	-	
postTx mnT1D518 20	3-23	1-26	1	4	LGGRELQDY	9	3-11	4	QQRSNWPLT	9	-	+	c	
postTx mnT1D518 25	3-30-3	3-22	2	4	DSNWGAHFDY	10	3-20	1	QQYGSSLWT	9	-	+	-	
postTx mnT1D518 26	3-23	1-26	1	4	TKWELLGSDYLFYD	14	1-33	5	QQYDNLPL	8	-	-	-	
postTx mnT1D518 28	3-30	3-22	2	4	DPRFYDSSGYLFDY	16	3-20	4	QQYGSSPH	8	-	-	-	
postTx mnT1D518 30	1-69	5-5	2	4	ARGYSYGQNDY	11	3-11	5	QQRSNWPPIIT	10	+	-	-	
postTx mnT1D518 34	3-23	2-2	3	5	DLIVVPAAIIRGWDFP	17	3-11	1	QQRSNWPRT	9	+	+	c	
postTx mnT1D518 37	4-61	4-23	3	4	STVVIDY	7	3-20	4	QQYGSSPRQLT	11	-	+	-	
postTx mnT1D518 42	3-23	3-9	2	6	DQYYDILTGYSYYYYGMDV	19	2-28	1	MQALQTPGT	9	-	-	-	
postTx mnT1D518 43	4-34	/	/	5	DDWFDP	6	4-1	1	QQYSTPRT	9	-	+	-	
	VH	D	RF	JH	CDR3(aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	HEp-2	Staining	
postTx mnT1D518 10	1-58	1-26	2	6	DPVGAVYYYYGMDV	14	1-44	3	AAWDDSLNGWV	11	+	-	-	
postTx mnT1D518 13	3-23	/	/	3	GTATGAFDI	9	1-40	1	QSYDSSLGYYV	11	-	-	-	
postTx mnT1D518 23	4-59	3-22	2	3	DRLRESSLTYYYDSSGYNDAFDI	24	1-51	1	GTWDSLSAGV	11	-	-	-	
postTx mnT1D518 31	3-23	3-22	2	4	MGLLFYFFDY	11	1-51	1	GTWDSLSAGV	11	-	-	-	

RF, reading frame; #, antibody failed to be expressed

-, non-reactive; +, reactive

c, diffuse cytoplasmic staining; A, actin staining; G, golgi staining; M, mitochondrial staining; N, nuclear staining

Appendix 1: Type 1 Diabetes TrialNet Study Group

Steering Committee: J.S. Skyler (University of Miami, Chair), M. Anderson (University of California, San Francisco), P. Antinozzi (Wake Forest University), M. Atkinson (University of Florida), M. Battaglia (San Raffaele University), D. Becker (University of Pittsburgh), P. Bingley (University of Bristol), E. Bosi (San Raffaele University), J. Buckner (Benaroya Research Institute), P. Colman (Walter & Eliza Hall Institute of Medical Research), L. DiMeglio (Indiana University), S. Gitelman, (University of California, San Francisco), R. Goland (Columbia University), P. Gottlieb (Barbara Davis Center for Childhood Diabetes), C. Greenbaum (Benaroya Research Institute), K. Herold (Yale University), R. Insel (Juvenile Diabetes Research Foundation), T. Kay (St Vincent's Institute of Medical Research), M. Knip (University of Helsinki), J. Krischer (University of South Florida), A. Lernmark (Skane University), J.B. Marks (University of Miami), A. Moran (University of Minnesota), J. Palmer (University of Washington), M. Peakman (King's College), L. Philipson (University of Chicago), A. Pugliese (University of Miami), P. Raskin (University of Texas Southwestern), M. Redondo (Baylor University), H. Rodriguez (University of South Florida), B. Roep (Leiden University Medical Center), W. Russell (Vanderbilt University), L. Spain (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]), D.A. Schatz (University of Florida), J. Sosenko (University of Miami), D. Wherrett (University of Toronto), D. Wilson (Stanford University), W. Winter (University of Florida), A. Ziegler (Forschergruppe Diabetes); Previous Members: C. Benoist (Joslin Diabetes Center), J. Blum (Indiana University), K. Bourcier, P. Chase (Barbara Davis Center for Childhood Diabetes), M. Clare-Salzler (University of Florida), R. Clynes (Columbia University), G. Eisenbarth (Barbara Davis Center for Childhood Diabetes), C. G. Fathman (Stanford University), G. Grave (National Institute of Child Health and Human Development), B. Hering (University of Minnesota), F. Kaufman (Children's Hospital Los Angeles), E. Leschek (NIDDK), J. Mahon (University of Western Ontario), K. Nanto-Salonen (University of Turku), G. Nepom (Benaroya Research Institute), T. Orban (Joslin Diabetes Center), R. Parkman (Children's Hospital Los Angeles), M. Pescovitz (Indiana University), J. Peyman (National Institute of Allergy and Infectious Disease), M. Roncarolo (San Raffaele University), P. Savage (NIDDK), O. Simell (University of Turku), R. Sherwin (Yale University), M. Siegelman (University of Texas Southwestern), A. Steck (Barbara Davis Center for Childhood Diabetes), J. Thomas (Vanderbilt University), M. Trucco (University of Pittsburgh), J. Wagner (University of Minnesota).

Executive Committee: Jay S. Skyler, Katarzyna Bourcier, Carla J. Greenbaum, Richard Insel, Jeffrey P. Krischer, Ellen Leschek, Lisa Rafkin, Lisa Spain. Past Members: Catherine Cowie, Mary Foulkes, Heidi Krause-Steinrauf, John M. Lachin, Saul Malozowski, John Peyman, John Ridge, Peter Savage, Stephanie J. Zafonte.

Chairman's Office: Jay S. Skyler, Carla J. Greenbaum, Norma S. Kenyon, Lisa Rafkin, Irene Santiago, Jay M. Sosenko.

TrialNet Coordinating Center (University of South Florida): Jeffrey P. Krischer, Brian Bundy, Michael Abbondandolo, Timothy Adams, Darlene Amado, Ilma Asif, Matthew Boonstra, David Boulware, Brian Bundy, Cristina Burroughs, David Cuthbertson, Mary Deemer, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson, Heather Guillette, Susan Geyer, Brian Hays, Courtney Henderson, Martha Henry, Kathleen Heyman, Belinda Hsiao, Christina Karges, Nichole Keaton, Amanda Kinderman, Pat Law, Ashely Leinbach, Cristin Linton, Shu Liu, Jennifer Lloyd, Jamie Malloy, Kristin Maddox, Julie Martin, Jessica Miller, Eric Milliot, Margaret Moore, Sarah Muller, Thuy Nguyen, Ryan O'Donnell, Vanessa Oduah, Jennifer Pilger, Amy Roberts, Kelly Sadler, Tina Stavros, Roy Tamura, Keith Wood, Ping Xu, Kenneth Young. Past Staff Members: Persida Alies, Franz Badias, Aaron Baker, Monica Bassi, Craig Beam, London Bounmananh, Susan Bream, Doug Freeman, Jessica Gough, Jinin Ginem, Moriah Granger, Mary Holloway Michelle Kieffer, Page Lane, Lavanya Nallamshetty, Yazandra Parrimon, Kate Paulus, Joy Ramiro, AQesha Luvon Ritzie, Archana Sharma, Audrey Shor, Xiaohong Song, Amanda Terry, Jeanne Weinberger, Margaret Wootten.

Previous Coordinating Center (George Washington University): John M. Lachin, Mary Foulkes, Pamela Harding, Heidi Krause-Steinrauf, Susan McDonough, Paula F. McGee, Kimberly Owens Hess, Donna Phoebus, Scott Quinlan, Erica Raiden.

NIDDK Staff: Judith Fradkin, Ellen Leschek, Lisa Spain. Past Member: Peter Savage.

Data Safety and Monitoring Board: Gerald Beck (Cleveland Clinic), Emily Blumberg (University of Pennsylvania), Chair, David Brillon (Cornell University), Rose Gubitosi-Klug (Case Western Reserve), Lori Laffel (Joslin Diabetes Center), Robert Veatch (Georgetown University), Dennis Wallace (Research Triangle Institute). Past Members: Jonathan Braun (University of California Los Angeles), Ake Lernmark (Lund University), Bernard Lo (University of California San Francisco), Herman Mitchell (Rho Inc.), Ali Naji (University of Pennsylvania), Jorn Nerup (University of Copenhagen), Trevor Orchard (University of Pittsburgh), Michael Steffes (University of Minnesota), Anastasios Tsiatis (North Carolina State University), Bernard Zinman (University of Toronto).

Infectious Disease Safety Committee: Brett Loechelt (Children's National Medical Center) (Medical Monitor), Lindsey Baden (Harvard University), Michael Green (University of Pittsburgh), Adriana Weinberg (University of Colorado).

Laboratory Directors: Santica Marcovina (University of Washington), Jerry P. Palmer, Adriana Weinberg, Liping Yu (University of Colorado Barbara Davis Center for Childhood Diabetes), Sunanda Babu (University of Colorado Barbara Davis Center for Childhood Diabetes) William Winter (University of Florida). Past Member: George S. Eisenbarth (late).

Protocol Chair Committee: Polly Bingley, Raphael Clynes, Linda DiMeglio, George Eisenbarth, Carla Greenbaum, Brian Hays, Jeffrey Krischer, Ellen Leschek, Jennifer Marks, Della Matheson, Lisa Rafkin, Henry Rodriguez, Jay Skyler, Jay Sosenko, Lisa Spain, Darrell Wilson.

Clinical Center Staff Involved in this Protocol:

Baylor College of Medicine: Maria Redondo, David Gomez, Andrene McDonald, Sandra Pena, Massimo Pietropaolo, Kathy Shippy.

Benaroya Research Institute, Seattle: Carla Greenbaum, Emily Batts, Tyler Brown, Jane Buckner, Angela Dove, Marissa Hammond, Deborah Hefty, Jani Klein, Kristen Kuhns, McKenzie Letlau, Sandra Lord, Marli McCulloch-Olson, Lisa Miller, Gerald Nepom, Jared Odegard, Mary Ramey, Elaine Sachter, Marissa St. Marie, Kimberly Stickney, Dana VanBuecken, Ben Vellek, Christine Webber. Past Members: Laurie Allen, Jenna Bollyk, Nicole Hilderman, Hebatullah Ismail, Steve Lamola, Srinath Sanda, Heather Vendettuoli, David Tridgell.

Children's Hospital Los Angeles: Roshanak Monzavi, Meredith Bock, Lynda Fisher, Mary Halvorson, Debra Jeandron, Mimi Kim, Jamie Wood. Past Members: Mitchell Geffner, Francine Kaufman, Robertson Parkman, Christine Salazar.

Columbia University, New York: Robin Goland, Raphael Clynes, Steve Cook, Matthew Freeby, Mary Pat Gallagher, Rachelle Gandica, Ellen Greenberg, Amy Kurland, Sarah Pollak, Amy Wolk. Past Members: Mary Chan, Linda Koplinae, Elizabeth Levine, Kelly Smith, Jeniece Trast.

Indiana University, Indianapolis: Linda DiMeglio, Janice Blum, Carmella Evans-Molina, Robin Hufferd, Bonnie Jagielo, Christy Kruse, Vanessa Patrick, Mark Rigby, Maria Spall, Kim Swinney, Jennifer Terrell. Past Members: Lyla Christner, LeeAnn Ford, Sheryl Lynch, Martha Menendez, Patricia Merrill, Mark Pescovitz (late), Henry Rodriguez.

Joslin Diabetes Center, Boston: Cielo Alleyn, David Baidal, Steve Fay, Jason Gaglia, Brittany Resnick, Sarah Szubowicz, Gordon Weir. Past Members: Ronald Benjamin, Debbie Conboy, Andrea

deManbey, Richard Jackson, Heyam Jalahej, Tihmar Orban, Alyne Ricker, Joseph Wolfsdorf, Hui H. Zhang.

Stanford University: Darrell Wilson, Tandy Aye, Bonita Baker, Karen Barahona, Bruce Buckingham, Kerry Esrey, Trudy Esrey, Garry Fathman, Radhika Snyder. Past Members: Beenu Aneja, Maya Chatav, Oralia Espinoza, Eliana Frank, Jenny Liu, Jennifer Perry, Rebecca Pyle, Alison Rigby, Kristin Riley, Adriana Soto.

University of California San Francisco: Stephen Gitelman, Saleh Adi, Mark Anderson, Ashley Berhel, Kathy Breen, Kathleen Fraser, Andrea Gerard-Gonzalez, Paula Jossan, Robert Lustig, Sara Moassesfar, Amy Mugg, David Ng, Priya Prahald, Martha Rangel-Lugo, Srinath Sanda, Joshua Tarkoff, Christine Torok, Rebecca Wesch. Past Members: Ivy Aslan, Jeanne Buchanan, Jennifer Cordier, Celia Hamilton, Louise Hawkins, Thu Ho, Anjali Jain, Karen Ko, Theresa Lee, Shelly Phelps, Stephen Rosenthal, Taninee Sahakitrungruang, Lorraine Stehl, Lisa Taylor, Marcia Wertz, Jenise Wong.

University of Chicago: Louis Philipson, Rosemary Briars, Nancy Devine, Elizabeth Littlejohn. Past Member: Tiffany Grant.

University of Colorado Barbara Davis Center for Childhood Diabetes, Denver: Peter Gottlieb, Georgeanna Klingensmith, Andrea Steck, Aimon Alkanani, Kimberly Bautista, Ruth Bedoy, Aaron Blau, Betsy Burke, Laraine Cory, MyLinh Dang, Lisa Fitzgerald-Miller, Alex Fouts, Vicky Gage, Satish Garg, Patricia Gesauldo, Raymond Gutin, Cory Hayes, Michelle Hoffman, Kaitlin Ketchum, Nyla Logsdan-Sackett, David Maahs, Laurel Messer, Lisa Meyers, Aaron Michels, Stesha Peacock, Marian Rewers, Perla Rodriguez, Flor Sepulbeda, Rachel Sippl, Andrea Steck, Iman Taki, Bao-Khan Tran, Tuan Tran, R. Paul Wadwa, Philip Zeitler. Past Members: Jennifer Barker, Sandra Barry, Laurie Birks, Leah Bomsburger, Terra Bookert, Leah Briggs, Patricia Burdick, Rosio Cabrera, Peter Chase, Erin Cobry, Amy Conley, Gabrielle Cook, Joseph Daniels, Dominic DiDomenico, Jennifer Eckert, Angelica Ehler, George Eisenbarth (late), Pamela Fain, Rosanna Fiallo-Scharer, Nicole Frank, Hannah Goettle, Michelle Haarhues, Sherrie Harris, Lauren Horton, John Hutton (late), Joy Jeffrey, Rachael Jenison, Kelly Jones, Whitney Kastelic, Maria Amelia King, Debbie Lehr, Jenna Lungaro, Kendra Mason, Heather Maurer, Luy Nguyen, Allison Proto, Jaime Realsen, Kristina Schmitt, Mara Schwartz, San Skovgaard, Jennifer Smith, Brandon Vanderwel, Mary Voelmle, Rebecca Wagner, Amy Wallace, Philip Walravens, Laurie Weiner, Becky Westerhoff, Emily Westfall, Katina Widmer, Hali Wright.

University of Florida, Gainesville: Desmond Schatz, Annie Abraham, Mark Atkinson, Miriam Cintron, Michael Clare- Salzler, Jessica Ferguson, Michael Haller, Jennifer Hosford, Diane Mancini, Hank Rohrs, Janet Silverstein, Jamie Thomas, William Winter. Past Members: Gloria Cole, Roberta Cook, Ryan Coy, Elena Hicks, Nancy Lewis.

University of Miami: Jennifer Marks, Alberto Pugliese, Carlos Blaschke, Della Matheson, Alberto Pugliese, Natalia Sanders-Branca, Jay Sosenko. Past Members: Luz Arazo Ray Arce, Mario Cisneros, Samir Sabbag.

University of Minnesota, Minneapolis: Antoinette Moran, Carrie Gibson, Brian Fife, Bernhard Hering, Christine Kwong, Janice Leschyshyn, Brandon Nathan, Beth Pappenfus, Anne Street. Past Members: Mary Ann Boes, Sarah Peterson Eck, Lois Finney, Theresa Albright Fischer, Andrea Martin, Chenai Jacqueline Muzamhindo, Missy Rhodes, Jennifer Smith, John Wagner, Bryan Wood.

University of Pittsburgh: Dorothy Becker, Kelli Delallo, Ana Diaz, Barbara Elnyczky, Ingrid Libman, Beata Pasek, Karen Riley, Massimo Trucco. Past Members: Brian Copemen, Diane Gwynn, Frederico Toledo.

University of South Florida: Henry Rodriguez, Sureka Bollepalli, Frank Diamond, Emily Eyth, Danielle Henson, Anne Lenz, Dorothy Shulman.

University of Texas Southwestern, Dallas: Phillip Raskin, Soumya Adhikari, Brian Dickson, Erin Dunnigan, Ildiko Lingvay, Lourdes Pruneda, Maria Ramos-Roman, Philip Raskin, Chanhaeng Rhee, John Richard, Mark Siegelman, Daytheon Sturges, Kathryn Sumpter, Perrin White.
Past Members: Marilyn Alford, Jamie Arthur, M. Larissa Aviles-Santa, Erica Cordova, Renee Davis, Stefani Fernandez, Steve Fordan, Tauri Hardin, Aris Jacobs, Polina Kaloyanova, Ivanna Lukacova-Zib, Sasan Mirfakhraee, Alok Mohan, Hiroshi Noto, Oralenda Smith, Nenita Torres.

University of Toronto: Diane Wherrett, Diana Balmer, Lesley Eisel, Roze Kovalakovska, Mala Mehan, Farah Sultan. Past Members: Brenda Ahenkorah, Jose Cevallos, Natasha Razack, Mary Jo Ricci, Angela Rhode, Mithula Srikandarajah, Rachel Steger.

Vanderbilt University, Nashville: William E. Russell, Margo Black, Faith Brendle, Anne Brown, Daniel Moore, Eric Pittel, Alyssa Robertson, April Shannon, James W. Thomas.

Yale University, New Haven: Kevan Herold, Laurie Feldman, Robert Sherwin, William Tamborlane, Stuart Weinzimer.

International Clinical Center Staff involved in this Protocol:

Hospital District of Southwest Finland: Jorma Toppari, Tiina Kallio, Maarit Kärkkäinen, Elina Mäntymäki, Tiina Niininen, Birgitta Nurmi, Petro Rajala, Minna Romo, Sointu Suomenrinne.
Past Members: Kirsti Näntö-Salonen, Olli Simell, Tuula Simell.

San Raffaele Hospital (Italy): Emanuele Bosi, Manuela Battaglia, Eleonora Bianconi, Riccardo Bonfanti, Pauline Grogan, Andrea Laurenzi, Sabina Martinenghi, Franco Meschi, Matteo Pastore.
Past Members: Luca Falqui, Maria Teresa Muscato, Matteo Viscardi.

University of Bristol (United Kingdom): Polly Bingley, Harriet Castleden, Nicola Farthing, Sam Loud, Claire Matthews, Jennifer McGhee, Ann Morgan, Joanna Pollitt. Past Members: Rebecca Elliot-Jones, Carole Wheaton.

University of Helsinki: Mikael Knip, Heli Siljander, Heli Suomalainen.

Walter and Eliza Hall Institute of Medical Research (Australia): Peter Colman, Felicity Healy, Shelley Mesfin, Leanne Redl, John Wentworth, Jinny Willis. Past Members: Maree Farley, Leonard Harrison, Christine Perry, Fiona Williams.

Appendix 2

Type 1 Diabetes TrialNet Pathway to Prevention Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development, through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01-DK103153, U01-DK085476, U01-DK103266 and the Juvenile Diabetes Research Foundation International (JDRF). The contents of this Article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or the JDRF.